Lantern is disrupting, reinventing and de-risking the traditional cancer drug development process by employing an adaptive “3R strategy” to rescue, reposition and revitalize abandoned drugs by harnessing the power of advanced genomics and artificial intelligence, also applicable for placing new drugs.
Download the white paper on Lantern’s AI -driven platform, RADR™ 3.0 and discover how we are leveraging AI to transform cancer therapy
Career Opportunity at Lantern Pharma
CLINICAL RESEARCH & SCIENTIFIC COLLABORATIONS LIAISON NEW YORK, NY & NORTHERN IRELAND
3 Reasons The Health AI Market is a Great Investment: PrecisionMedicine using Genetic Signature Targeting – Arun Asaithambi Co-founder of Lantern Pharma Inc is featured in Entrepreneur.com
Precision Oncology Company Lantern Pharma to Showcase Artificial Intelligence Approach
Lantern Pharma Joins Genomics England to Advance Their Precision Oncology Platform